J.P. Morgan SE - Stabilisation Notice

Bausch Health Companies

19/06/2025 10:01

RNS Number : 5753N

J.P. Morgan SE

19 June 2025

 

19th June 2025

Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful.

Bausch + Lomb Netherlands B.V. (Dutch Co-Issuer) and Bausch & Lomb Incorporated (US Co-Issuer)

Post-stabilisation Period Announcement

Further to the pre-stabilisation period announcement dated 18th June 2025, J.P. Morgan SE, (contact: Rishik Arya +33 1 40 15 41 59) hereby gives notice that no stabilisation (within the meaning of Article 3.2(d) of the Market Abuse Regulation (EU/596/2014) or the rules of the Financial Conduct Authority) was undertaken by the Stabilisation Manager(s) named below in relation to the offer of the following securities.

Issuer:
Bausch + Lomb Netherlands B.V. (Dutch Co-Issuer) and Bausch & Lomb Incorporated (US Co-Issuer)
Guarantor (if any):
N/A
Aggregate nominal amount:
EUR 675mm
Description:
EUR 5.5yr FRN
Senior Secured Notes
RegS /144A
Listing: The international stock exchange
Stabilisation Manager(s):
J.P. Morgan S.E (Stabilisation coordinator)
Barclays (Stabilisation manager)
Citi (Stabilisation manager)
Goldman Sachs (Stabilisation manager)
HSBC (Stabilisation manager)
Wells Fargo (Stabilisation manager)
Offer price:
99.50%

 

This announcement is for information purposes only and does not constitute an invitation or offer to underwrite, subscribe for or otherwise acquire or dispose of any securities of the Issuer in any jurisdiction

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
STAFIFETRDIALIE